Gland Pharma Reports Strong FY26 Results: Profit Hits ₹10,455M, Up 49.7%, Proposes ₹20 Dividend

Gland Pharma announced its audited financial results for the fiscal year ended March 31, 2026. The company reported consolidated revenue of ₹64,307 million, marking a 14.5% increase from ₹56,165 million in FY25. Adjusted Profit After Tax (PAT) surged 49.7% to ₹10,455 million, up from ₹6,985 million in the previous fiscal year.

Financial Approval and Operational Highlights

The Board of Directors met on May 15, 2026, to approve the audited financial results for FY26 and recommended a final dividend of ₹20 per equity share. This strong performance was supported by significant operational progress.

In the fourth quarter of FY26 (Q4 FY26), Gland Pharma launched five new molecules in the US market, including Dalbavancin and Brimonidine. The company also advanced its US regulatory strategy, submitting 8 ANDAs and securing 11 approvals during Q4 FY26, bringing its cumulative US filing total to 388 with 337 approvals. Additionally, Gland Pharma signed a new contract manufacturing (CDMO) agreement for a complex injectable using a Nano Drug Delivery System in the oncology segment. R&D expenses for Q4 FY26 were ₹506 million, dedicated to developing complex products.

Investor Value and Strategic Wins

The substantial growth in revenue and profit, alongside the proposed dividend, highlights Gland Pharma's enhanced operational efficiency and market execution. The company's strategic focus on launching new molecules and expanding its contract manufacturing (CDMO) services is clearly translating into positive financial outcomes.

This performance demonstrates Gland Pharma's capability to compete effectively in the pharmaceutical sector by leveraging its manufacturing and development strengths. The recommended dividend offers a direct return to shareholders, increasing the stock's appeal.

About Gland Pharma

Gland Pharma is a prominent generic injectable manufacturer based in India, with a strong emphasis on the US market. Its product offerings include sterile injectables, oncology treatments, and complex injectable products, supplemented by contract development and manufacturing (CDMO) services. Over the past two years, Gland Pharma has focused on launching new molecules in the US, expanding its ANDA filings and approvals. The company has consistently highlighted its research and development capabilities for complex generics and its growing CDMO business.

Impact for Shareholders

Shareholders are poised to benefit from the recommended final dividend of ₹20 per equity share, subject to approval at the Annual General Meeting (AGM). The company's improved financial health is evident in the strong growth across both revenue and profit. Gland Pharma is strengthening its US market position via new product launches and regulatory approvals, while also expanding its presence in the high-margin CDMO segment.

Potential Risks

The results presentation includes forward-looking statements, which are subject to risks and uncertainties. These could include changes in general economic conditions, increased competition, or regulatory and technological shifts.

Market Context: Peers and Trends

Competitors like Dr. Reddy's Laboratories and Cipla are also expanding their US generics portfolios and complex product pipelines. This reflects a competitive yet growing market. Divi's Laboratories, a key contract manufacturer for global pharmaceutical firms, illustrates the broader trend of growth in contract manufacturing within the Indian pharmaceutical industry.

Looking Ahead: Key Investor Focus Areas

Investors will be watching for shareholder approval of the recommended final dividend at the upcoming AGM, and its timely payout. Key areas for tracking include the performance of the five new molecules launched in the US in Q4 FY26, continued progress in US ANDA filings and approvals, and developments within the CDMO pipeline, especially concerning new contracts for complex injectables.